SPDR Pharma ETF

XPH-N

NYSEARCA:XPH

44.10
0.77 (1.72%)

Analysis and Opinions about XPH-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
September 11, 2019

Lots of rhetoric around pharma around election time, but not a lot gets changed. An equal weight ETF. Hasn't done well. Prefers Vanguard's VHT in the US, cheaper and a market weighted strategy with Pfizer, Merck, and Abbott Labs.

Show full opinionHide full opinion
SPDR Pharma ETF (XPH-N)
September 11, 2019

Lots of rhetoric around pharma around election time, but not a lot gets changed. An equal weight ETF. Hasn't done well. Prefers Vanguard's VHT in the US, cheaper and a market weighted strategy with Pfizer, Merck, and Abbott Labs.

Stan Wong

Unlock Ratings

Price
$37.600
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
August 31, 2018

This is in an incredibly strong trend, so be careful of the entry point. Healthcare might give a little more opportunity like the IYH-N ETF or an equal weight XLV-N ETF.

Show full opinionHide full opinion
SPDR Pharma ETF (XPH-N)
August 31, 2018

This is in an incredibly strong trend, so be careful of the entry point. Healthcare might give a little more opportunity like the IYH-N ETF or an equal weight XLV-N ETF.

BUY
BUY
December 12, 2016

We have a base. It was beat up by Hillary Clinton. The sector is in a secular bull market, however. This is a good place to get your initial allocation. We come into a seasonal period soon. There is decent value.

Show full opinionHide full opinion
SPDR Pharma ETF (XPH-N)
December 12, 2016

We have a base. It was beat up by Hillary Clinton. The sector is in a secular bull market, however. This is a good place to get your initial allocation. We come into a seasonal period soon. There is decent value.

PAST TOP PICK
PAST TOP PICK
November 25, 2016

(A Top Pick Aug 10/16. Down 12.87%.) This has been frustrating with controversies and the possibility of a Clinton presidency. Now all of that has come off, and this has gapped higher from a depressed level. It is now testing that gap support at around $39. If it can hold that, there might actually be a play here. If you own this, continue to hold as there might be some good things happening.

Show full opinionHide full opinion
SPDR Pharma ETF (XPH-N)
November 25, 2016

(A Top Pick Aug 10/16. Down 12.87%.) This has been frustrating with controversies and the possibility of a Clinton presidency. Now all of that has come off, and this has gapped higher from a depressed level. It is now testing that gap support at around $39. If it can hold that, there might actually be a play here. If you own this, continue to hold as there might be some good things happening.

TOP PICK
TOP PICK
August 10, 2016

Pharmaceutical stocks tend to do well between August and November. Between August 13 and November 21, it tends to gain an average of 5.5%, and has been positive 80% of the time over the past 20 years. This is the period were shipments of pharmaceuticals and medicines tend to increase for the start of the cold and flu season. The 3rd quarter tends to be the best quarter for some of these Pharma stocks. This ETF owns a wide variety of pharmaceutical stocks and not all of them are high yielding, but you tend to benefit from the seasonal strength. Dividend yield of about 0.5%.

Show full opinionHide full opinion
SPDR Pharma ETF (XPH-N)
August 10, 2016

Pharmaceutical stocks tend to do well between August and November. Between August 13 and November 21, it tends to gain an average of 5.5%, and has been positive 80% of the time over the past 20 years. This is the period were shipments of pharmaceuticals and medicines tend to increase for the start of the cold and flu season. The 3rd quarter tends to be the best quarter for some of these Pharma stocks. This ETF owns a wide variety of pharmaceutical stocks and not all of them are high yielding, but you tend to benefit from the seasonal strength. Dividend yield of about 0.5%.

COMMENT
COMMENT
June 30, 2016

Which stocks for RESP and University in 8 years? He would use healthcares such as SPDR Health Care (XLV-N) or SPDR Pharma (XPH-N). These are in a secular bull market. You could also use Van Eck Vectors Biotech (BBH-Q). This gives you a little bit of mix of all 3 sectors. He would suggest 40% and 40% on the first 2 and maybe 20% in the Biotechs.

Show full opinionHide full opinion

Which stocks for RESP and University in 8 years? He would use healthcares such as SPDR Health Care (XLV-N) or SPDR Pharma (XPH-N). These are in a secular bull market. You could also use Van Eck Vectors Biotech (BBH-Q). This gives you a little bit of mix of all 3 sectors. He would suggest 40% and 40% on the first 2 and maybe 20% in the Biotechs.

PAST TOP PICK
PAST TOP PICK
November 18, 2013

(A Top Pick Aug 22/13. Up 14.37%.) Probably the only play that has seasonal strength through to the end of the year. Pharmaceutical stocks tend to peak right around now.

Show full opinionHide full opinion
SPDR Pharma ETF (XPH-N)
November 18, 2013

(A Top Pick Aug 22/13. Up 14.37%.) Probably the only play that has seasonal strength through to the end of the year. Pharmaceutical stocks tend to peak right around now.

TOP PICK
TOP PICK
August 22, 2013

Pharmaceuticals tend to do well from right about now through to the end of the year. He had read where Obama care would be injecting $10 billion-$35 billion in additional profits into the pharmaceutical industry over the next 10 years.

Show full opinionHide full opinion
SPDR Pharma ETF (XPH-N)
August 22, 2013

Pharmaceuticals tend to do well from right about now through to the end of the year. He had read where Obama care would be injecting $10 billion-$35 billion in additional profits into the pharmaceutical industry over the next 10 years.

Showing 1 to 8 of 8 entries
  • «
  • 1
  • »

SPDR Pharma ETF(XPH-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for SPDR Pharma ETF is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

SPDR Pharma ETF(XPH-N) Frequently Asked Questions

What is SPDR Pharma ETF stock symbol?

SPDR Pharma ETF is a American stock, trading under the symbol XPH-N on the NYSE Arca (XPH). It is usually referred to as AMEX:XPH or XPH-N

Is SPDR Pharma ETF a buy or a sell?

In the last year, 1 stock analyst published opinions about XPH-N. 0 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for SPDR Pharma ETF.

Is SPDR Pharma ETF a good investment or a top pick?

SPDR Pharma ETF was recommended as a Top Pick by Stan Wong on 2019-09-11. Read the latest stock experts ratings for SPDR Pharma ETF.

Why is SPDR Pharma ETF stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is SPDR Pharma ETF worth watching?

In the last year, there was no coverage of SPDR Pharma ETF published on Stockchase.

What is SPDR Pharma ETF stock price?

On 2020-02-25, SPDR Pharma ETF (XPH-N) stock closed at a price of $44.1.